Replay available

Abivax SA (ABVX) Q4 2023 Earnings Call

Abivax SA (NASDAQ: ABVX) Q4 2023 earnings conference call, held 2024-04-08. Replay captured from the company's public earnings webcast.

Mon, April 8, 2024 at 8:30 AMendedReplay
Abivax SA (ABVX) Q4 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Vikram Purohit

Analyst, Morgan Stanley

Mark DeGaradell

CEO

Julian Harrison

Analyst, BTIG

Patrick Malloy

Senior Vice President, Investor Relations

Thomas Smith

Analyst, LeanRig Partners

Didier Scherer

Chief Scientific Officer

Sheldon Sloan

Chief Medical Officer

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. Welcome to Abibag's conference call to discuss 2023 financial results and business update. My name is Sandra and I'll be your operator for today's call. At this time, all participants are in listen-only mode. Later, we will conduct a Q&A question and answer session and instructions will follow at that time. As a reminder, this call is being recorded at Abibag's request. Now, I would like to introduce your host for today's call, Patrick Malloy, Senior Vice President, Investor Relations. Pat, please go ahead. Thank you, Operator, and good morning and good afternoon to everyone. Welcome to today's call, during which we'll provide an update on our financial results for the full year ended December 31st, 2023, as well as key program updates across business. On April 2nd, we issued a press release summarizing our financial results, and on April 5th, we filed our 20F and universal registration document, all of which can be found on the ABVAC's website. Before we get started, I'd like to remind everyone that during today's discussion, we'll make statements about our future expectations, plans, and prospects that constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Security and Litigations Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements are a result of important factors, including those risk factors discussed in our SEC filings, and we are not under any obligation to update these forward-looking statements. In just a few moments, I'll be handing the call over to our CEO, Mark DeGaradell, who will provide the financial results and business up to date. Following the prepared remarks, we'll move to a question and ans...

More from Abivax Sa